Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).
Primo N. Lara, MD
Advertisement
Articles by Primo N. Lara, MD
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the potential role of IDO inhibitors in the treatment of patients with renal cell carcinoma.
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat in renal cell carcinoma.
Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses epacadostat plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).
Advertisement
Latest Updated Articles
Dr. Lara on Epacadostat Plus Pembrolizumab in RCCJune 23rd 2017
Dr. Lara Discusses Epacadostat in Renal Cell CarcinomaJuly 19th 2017
Dr. Lara on the Role of Sunitinib for Renal Cell CarcinomaAugust 2nd 2017
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5